Generally, IGF-1 and IGFBP-3, HOMA beta cell function, and free testosterone levels may serve as potential biomarkers of sarcopenia in hip-fracture patients; however, further evaluation of the relationship between the IGF-I pathway, insulin homeostasis, and its effect on skeletal muscle regulation is needed. This evidence concerns the gene IGFBP3 and sarcopenia.